BioVie Inc. (BIVI)

US — Healthcare Sector
Peers: KZIA  ELAB  CANF  CERO  TOVX  GLMD  OCEA  ARTL  INM  LIPO 

Automate Your Wheel Strategy on BIVI

With Tiblio's Option Bot, you can configure your own wheel strategy including BIVI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BIVI
  • Rev/Share 0.0
  • Book/Share 4.7793
  • PB 0.2521
  • Debt/Equity 0.0134
  • CurrentRatio 15.8276
  • ROIC -0.7614

 

  • MktCap 9082662.0
  • FreeCF/Share -3.5421
  • PFCF -0.4918
  • PE -0.3392
  • Debt/Assets 0.0124
  • DivYield 0
  • ROE -0.8262

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BioVie hits enrolment milestone in early Parkinson's trial, data due later this year
BIVI
Published: January 16, 2026 by: Proactive Investors
Sentiment: Positive

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disease, putting the group on track for key data later this year. The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been treated with standard levodopa therapy.

Read More
image for news BioVie hits enrolment milestone in early Parkinson's trial, data due later this year
What Makes BioVie (BIVI) a New Buy Stock
BIVI
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive

BioVie (BIVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news What Makes BioVie (BIVI) a New Buy Stock
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
BIVI
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here .

Read More
image for news BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

About BioVie Inc. (BIVI)

  • IPO Date 2020-09-18
  • Website https://bioviepharma.com
  • Industry Biotechnology
  • CEO Cuong Viet Do
  • Employees 14
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.